Recombinant adeno-associated virus vector carrying the thrombomodulin lectin-like domain for the treatment of abdominal aortic aneurysm.

[1]  J. Golledge,et al.  Angiopoietin-2 attenuates angiotensin II-induced aortic aneurysm and atherosclerosis in apolipoprotein E-deficient mice , 2016, Scientific Reports.

[2]  J. Grieger,et al.  Manufacturing of recombinant adeno-associated viral vectors for clinical trials , 2016, Molecular therapy. Methods & clinical development.

[3]  D. Schaffer,et al.  Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Hua-Lin Wu,et al.  Toll-Like Receptor 4 Is Essential in the Development of Abdominal Aortic Aneurysm , 2016, PloS one.

[5]  Hua-Lin Wu,et al.  Membrane-Bound Thrombomodulin Regulates Macrophage Inflammation in Abdominal Aortic Aneurysm , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[6]  Jeng-Shin Lee,et al.  Development of Recombinant Adeno-Associated Virus Serotype 2/8 Carrying Kringle Domains of Human Plasminogen for Sustained Expression and Cancer Therapy. , 2015, Human gene therapy.

[7]  R. Samulski,et al.  Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspective. , 2015, Human gene therapy.

[8]  T. van der Poll,et al.  Mice Lacking the Lectin-Like Domain of Thrombomodulin Are Protected Against Melioidosis , 2014, Critical care medicine.

[9]  Hua-Lin Wu,et al.  Recombinant Human Thrombomodulin Suppresses Experimental Abdominal Aortic Aneurysms Induced by Calcium Chloride in Mice , 2013, Annals of surgery.

[10]  Chuan-Fa Chang,et al.  Recombinant Lectin-Like Domain of Thrombomodulin Suppresses Vascular Inflammation by Reducing Leukocyte Recruitment via Interacting With Lewis Y on Endothelial Cells , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[11]  Weifeng Shen,et al.  Spatiotemporal Expression of Matrix Metalloproteinases (MMPs) is Regulated by the Ca2+-Signal Transducer S100A4 in the Pathogenesis of Thoracic Aortic Aneurysm , 2013, PloS one.

[12]  Wanjun Liu,et al.  CYP2J2 overexpression increases EETs and protects against angiotensin II-induced abdominal aortic aneurysm in mice[S] , 2013, Journal of Lipid Research.

[13]  Y. Okada,et al.  High-mobility group box 1 protein blockade suppresses development of abdominal aortic aneurysm. , 2012, Journal of cardiology.

[14]  Hua-Lin Wu,et al.  The role of thrombomodulin lectin-like domain in inflammation , 2012, Journal of Biomedical Science.

[15]  Jeng-Shin Lee,et al.  The recombinant lectin-like domain of thrombomodulin inhibits angiogenesis through interaction with Lewis Y antigen. , 2012, Blood.

[16]  K. High,et al.  Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges , 2011, Nature Reviews Genetics.

[17]  A. Coyle,et al.  HMGB1 and RAGE in inflammation and cancer. , 2010, Annual review of immunology.

[18]  K. Kent,et al.  The novel function of advanced glycation end products in regulation of MMP-9 production. , 2010, The Journal of surgical research.

[19]  Gene Kim,et al.  S100A12 Mediates Aortic Wall Remodeling and Aortic Aneurysm , 2010, Circulation research.

[20]  D. Milewicz,et al.  An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. , 2009, The Journal of clinical investigation.

[21]  K. Kent,et al.  Anti-Receptor for Advanced Glycation End Products Therapies as Novel Treatment for Abdominal Aortic Aneurysm , 2009, Annals of surgery.

[22]  J. Mactaggart,et al.  Blocking TNF-α Attenuates Aneurysm Formation in a Murine Model1 , 2009, The Journal of Immunology.

[23]  R. Morishita,et al.  Pharmacological treatment of abdominal aortic aneurysm. , 2009, Cardiovascular research.

[24]  Chi‐Huey Wong,et al.  Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. , 2008, Blood.

[25]  P. Marsden,et al.  Activated protein C and diabetic nephropathy. , 2008, The New England journal of medicine.

[26]  M. Matsuzaki,et al.  Turning back the clock: regression of abdominal aortic aneurysms via pharmacotherapy , 2007, Journal of Molecular Medicine.

[27]  M. Daha,et al.  The lectin‐like domain of thrombomodulin interferes with complement activation and protects against arthritis , 2006, Journal of thrombosis and haemostasis : JTH.

[28]  Peter Libby,et al.  Inflammation and cellular immune responses in abdominal aortic aneurysms. , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[29]  Hiroshi Yamamoto,et al.  The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. , 2005, The Journal of clinical investigation.

[30]  C. Esmon.  Do-all receptor takes on coagulation, inflammation , 2005, Nature Medicine.

[31]  L. Brown.  Commercial challenges of protein drug delivery , 2005, Expert opinion on drug delivery.

[32]  E. Conway,et al.  Novel functions of thrombomodulin in inflammation , 2004, Critical care medicine.

[33]  Alan Daugherty,et al.  Mouse Models of Abdominal Aortic Aneurysms , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[34]  Hua-Lin Wu,et al.  Thrombomodulin-mediated Cell Adhesion , 2003, Journal of Biological Chemistry.

[35]  W. Hsueh,et al.  Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. , 2003, The Journal of clinical investigation.

[36]  D. C. Brewster,et al.  Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. , 2003, Journal of vascular surgery.

[37]  Timothy C Greiner,et al.  Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. , 2002, The Journal of clinical investigation.

[38]  A. Schmidt,et al.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.

[39]  Alberto Smith,et al.  Experimental techniques and models in the study of the development and treatment of abdominal aortic aneurysm , 1999, The British journal of surgery.

[40]  R. Samulski,et al.  Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus , 1998, Journal of Virology.

[41]  F G Fowkes,et al.  Expansion rates of abdominal aortic aneurysm: current limitations in evaluation. , 1997, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[42]  I. Maruyama,et al.  Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation , 2011, Journal of thrombosis and haemostasis : JTH.

[43]  S. Weger,et al.  Viral vectors for gene transfer: current status of gene therapeutics. , 2010, Handbook of experimental pharmacology.

[44]  Arjan W. Griffioen,et al.  Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1) , 2008, Angiogenesis.

[45]  J. Golledge,et al.  Atvb in Focus Abdominal Aortic Aneurysms: Pathophysiological Mechanisms and Clinical Implications Abdominal Aortic Aneurysm Pathogenesis and Implications for Management , 2022 .